Lori Daiello

About

Lori Daiello, PharmD, ScM, is an Associate Professor of Health Services, Policy and Practice (Research) and Neurology (Research) at Brown University. She is a cognitive aging researcher with primary interests in novel biomarkers of neurodegeneration, preclinical Alzheimer's Disease, delirium, and perioperative neurocognitive disorders. Her work is informed by a long-standing interest in the impact of prescription medications on late-life cognitive and functional outcomes, collaborating with colleagues at the School of Public Health and the Department of Psychiatry and Human Behavior. Dr. Daiello is the principal investigator of an NIH-funded study examining postoperative delirium and persistent cognitive impairment among older adults undergoing major surgeries. Her research utilizes brain MRI and other measures to investigate blood-brain barrier dysfunction and neuroinflammation as mediators of perioperative cognitive disorders and the risk of late-onset Alzheimer's Disease. Her affiliations include the Department of Health Services, Policy and Practice, and the Department of Neurology at Brown University, with research areas spanning Alzheimer's disease, dementia, brain health, medication adverse effects, and geriatric psychopharmacology.

Research topics

• Medicine
• Internal medicine
• Psychology
• Pathology
• Neuroscience
• Psychiatry
• Oncology
• Machine Learning
• Computer Science
• Artificial Intelligence

Selected publications

• Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology

  Scientific Reports · 2020 · 133 citations

  Causal Structure Discovery (CSD) is the problem of identifying causal relationships from large quantities of data through computational methods. With the limited ability of traditional association-based computational methods to discover causal relationships, CSD methodologies are gaining popularity. The goal of the study was to systematically examine whether (i) CSD methods can discover the known causal relationships from observational clinical data and (ii) to offer guidance to accurately disco…

  DOI

• Anatomically interpretable deep learning of brain age captures domain-specific cognitive impairment

  Proceedings of the National Academy of Sciences · 2023 · 116 citations

  = 359). In individuals with MCI (54% of whom were diagnosed with dementia within 10.9 y from MRI acquisition), BA is significantly better than CA in capturing dementia symptom severity, functional disability, and executive function. Profiles of sex dimorphism and lateralization in brain aging also map onto patterns of neuroanatomic change that reflect cognitive decline. Significant associations between BA and neurocognitive measures suggest that the proposed framework can map, systematically, th…

  DOI

• Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status

  Translational Psychiatry · 2021 · 68 citations

  Plasma phosphorylated-tau181 (p-tau181) showed the potential for Alzheimer's diagnosis and prognosis, but its role in detecting cerebral pathologies is unclear. We aimed to evaluate whether it could serve as a marker for Alzheimer's pathology in the brain. A total of 1189 participants with plasma p-tau181 and PET data of amyloid, tau or FDG PET were included from ADNI. Cross-sectional relationships of plasma p-tau181 with PET biomarkers were tested. Longitudinally, we further investigated whethe…

  DOI

• Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study

  Translational Psychiatry · 2021 · 65 citations

  F-AV-1451 tau PET (baseline age 73.9 ± 7.7 years, 375 female) were stratified into five stages by a topographic PET staging scheme. Cognitive trajectories and clinical progression were compared across stages with or without further dichotomy of amyloid status, using linear mixed-effect models and Cox proportional hazard models. Significant cognitive decline was first observed in stage 1 when tau levels only increased in transentorhinal regions. Rates of cognitive decline and clinical progression…

  DOI

• Anticholinergic/Sedative Drug Burden and Subjective Cognitive Decline in Older Adults at Risk of Alzheimer’s Disease

  The Journals of Gerontology Series A · 2020 · 27 citations

  BACKGROUND: Anticholinergic/sedative drug use, measured by the Drug Burden Index (DBI), has been linked to cognitive impairment in older adults. Subjective cognitive decline (SCD) may be among the first symptoms patients with Alzheimer's disease (AD) experience. We examined whether DBI values are associated with SCD in older adults at risk of AD. We hypothesized that increased DBI would be associated with greater SCD at older ages. METHOD: Two-hundred-six community-dwelling, English-speaking adu…

  DOI

Recent grants

• NIH Grant R03AG050232

  NIH · $177k · 2018

• Blood-Brain Barrier Disruption as a Biomarker for Perioperative Neurocognitive Disorder:Cognitive Recovery after Elective Surgery

  NIH · $4.2M · 2019–2026

• NIH Grant K08HS017735

  NIH · $754k · 2014

Frequent coauthors

• Brian R. Ott

  Brown University

  217 shared

• Andrew R. Zullo

  Brown University

  177 shared

• Jonathan Drake

  Alzheimer’s Disease Neuroimaging Initiative

  121 shared

• Sarah D. Berry

  Hebrew SeniorLife

  115 shared

• Richard N. Jones

  Butler Hospital

  109 shared

• Douglas P. Kiel

  Hebrew SeniorLife

  100 shared

• Geoffrey Tremont

  Providence College

  75 shared

• Seth A. Margolis

  Brown University

  70 shared

Education

• Other, Pharmacy

  Brown University

• Other, Public Health

  Brown University

Similar researchers at Brown University

• Karen Furieh-148
• Rena Wingh-146
• Lawrence Priceh-132